Results 1 to 10 of about 347,846 (181)

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics

Frontiers in Oncology, 2019
The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations across multiple cancer types including both solid and hematologic malignancies has revolutionized our understanding of oncogenesis in these malignancies and the ...
D. Golub, N. Iyengar, S. Dogra, T. Wong, Devin Bready, Karen H. K. Tang, A. Modrek, D. Placantonakis   +7 more
semanticscholar   +3 more sources

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia

Biomarker Research, 2019
Isocitrate dehydrogenase (IDH) is a key enzyme involved in the conversion of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid (TCA) cycle. IDH mutation produces a neomorphic enzyme, which can lead to the abnormal accumulation of R-2-HG and ...
Xiaoyan Liu, Y. Gong
semanticscholar   +3 more sources

Physiological regulation of isocitrate dehydrogenase and the role of 2-oxoglutarate in Prochlorococcus sp. strain PCC 9511. [PDF]

PLoS ONE, 2014
The enzyme isocitrate dehydrogenase (ICDH; EC 1.1.1.42) catalyzes the oxidative decarboxylation of isocitrate, to produce 2-oxoglutarate. The incompleteness of the tricarboxylic acids cycle in marine cyanobacteria confers a special importance to ...
María Agustina Domínguez-Martín, Antonio López-Lozano, Jesús Diez, Guadalupe Gómez-Baena, Oriol Alberto Rangel-Zúñiga, José Manuel García-Fernández   +5 more
doaj   +5 more sources

Isocitrate protects DJ-1 null dopaminergic cells from oxidative stress through NADP+-dependent isocitrate dehydrogenase (IDH) [PDF]

PLoS Genetics, 2017
DJ-1 is one of the causative genes for early onset familiar Parkinson’s disease (PD) and is also considered to influence the pathogenesis of sporadic PD. DJ-1 has various physiological functions which converge on controlling intracellular reactive oxygen
Jinsung Yang, Min Ju Kim, Woongchang Yoon, E. Y. Kim, Hyunjin Kim, Y. Lee, B. Min, Kyung Shin Kang, J. Son, H. Park, Jongkyeong Chung, H. Koh   +11 more
semanticscholar   +2 more sources

Expression of IDH1, ATRX, p53 in Diagnosis of Gliomas as Per 2016 WHO Classification [PDF]

Journal of Clinical and Diagnostic Research, 2023
Introduction: The 2016 World Health Organisation (WHO) classification of tumours of the Central Nervous System (WHO CNS 2016 classification) is used to classify diffuse gliomas as astrocytoma, Oligodendroglioma (ODG), glioblastoma which are three ...
Lokesh Kumar, Manjiri Karandikar, NS Mani, RC Nimbargi   +3 more
doaj   +1 more source

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.

Neuro-Oncology, 2022
Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant primary brain tumors diagnosed in patients younger than 50, constituting an important cause of morbidity and mortality.
Julie J. Miller, L. G. Gonzalez Castro, S. McBrayer, M. Weller, T. Cloughesy, J. Portnow, O. Andronesi, J. Barnholtz-Sloan, B. Baumert, M. Berger, W. Bi, R. Bindra, D. Cahill, Susan M. Chang, J. Costello, C. Horbinski, Raymond Y Huang, R. Jenkins, K. Ligon, I. Mellinghoff, L. Nabors, M. Plattén, D. Reardon, D. Shi, D. Schiff, W. Wick, Hai Yan, A. von Deimling, M. J. van den Bent, W. Kaelin, P. Wen   +30 more
semanticscholar   +1 more source

Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas. [PDF]

PLoS ONE, 2015
Isocitrate dehydrogenase 1 gene mutations are found in most World Health Organization grade II and III gliomas and secondary glioblastomas. Isocitrate dehydrogenase 1 mutations are known to have prognostic value in high-grade gliomas.
Ming-Yang Li, Yin-Yan Wang, Jin-Quan Cai, Chuan-Bao Zhang, Kuan-Yu Wang, Wen Cheng, Yan-Wei Liu, Wei Zhang, Tao Jiang   +8 more
doaj   +1 more source

Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma

Oncogene, 2021
Brain tumors actively reprogram their cellular metabolism to survive and proliferate, thus offering potential therapeutic opportunities. Over the past decade, extensive research has been done on mutant IDH enzymes as markers of good prognosis in ...
Gabriel Alzial, Ophélie Renoult, F. Paris, C. Gratas, A. Clavreul, C. Pecqueur   +5 more
semanticscholar   +1 more source

Pattern of Recurrence of Glioblastoma Versus Grade 4 IDH-Mutant Astrocytoma Following Chemoradiation: A Retrospective Matched-Cohort Analysis

Technology in Cancer Research & Treatment, 2022
Background and Purpose: To quantitatively compare the recurrence patterns of glioblastoma (isocitrate dehydrogenase-wild type) versus grade 4 isocitrate dehydrogenase-mutant astrocytoma (wild type isocitrate dehydrogenase and mutant isocitrate ...
James Stewart PhD, Arjun Sahgal MD, Aimee K M Chan MSc, Hany Soliman MD, Chia-Lin Tseng MD, Jay Detsky MD, PhD, Sten Myrehaug MD, Eshetu G Atenafu MSc, Ali Helmi MD, James Perry MD, Julia Keith MD, Mary Jane Lim-Fat MD, MSc, David G Munoz MD, MSc, Gelareh Zadeh MD, PhD, David B Shultz MD, PhD, Sunit Das MD, PhD, Catherine Coolens PhD, Paula Alcaide-Leon MD, Pejman Jabehdar Maralani MD   +18 more
doaj   +1 more source

Stochastic Microsensors Based on Carbon Nanotubes for Molecular Recognition of the Isocitrate Dehydrogenases 1 and 2

Nanomaterials, 2022
Two three-dimensional (3D) stochastic microsensors based on immobilization of protoporphyrin IX (PIX) in single-walled carbon nanotubes (SWCNT) and multi-walled carbon nanotubes (MWCNT) decorated with copper (Cu) and gold (Au) nanoparticles were designed
Raluca-Ioana Stefan-van Staden, Catalina Cioates Negut, Sorin Sebastian Gheorghe, Paula Sfirloaga   +3 more
doaj   +1 more source